Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list.

TheFly reported on June 16 that Canaccord analyst Whitney Ijem increased the price target on RYTM to $151 from $143 while maintaining a Buy rating. The update followed a positive interim review from the Phase 2 study of setmelanotide in Prader-Willi syndrome (PWS). Canaccord highlighted continued BMI improvements with longer treatment exposure, with reductions reaching 3.06% at six months compared with 1.84% at three months. The firm also noted that 8 of 10 patients with moderate to severe baseline hyperphagia achieved a clinically meaningful reduction of at least 7 points on the HQ-CT assessment.

On June 15, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced new data presentations from ENDO 2026 highlighting results from its MC4R agonist programs in acquired hypothalamic obesity, Bardet-Biedl syndrome, and Prader-Willi syndrome. The company reported positive findings showing improvements in weight-related outcomes and hyperphagia across multiple patient populations. Data included long-term setmelanoti

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/rhythm-pharmaceuticals-inc-rytm-stock-132221610.html)